Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations.
Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations.
复制标题
DOI：
10.1186/1472-6963-14-201
复制
发表时间：
2014-05-02
影响因子：
2.8
通讯作者：
Ciaranello A
中科院分区：
文献类型：
--
作者：
Doherty K;Essajee S;Penazzato M;Holmes C;Resch S;Ciaranello A
儿科抗逆转录病毒疗法(ART)已被证明可显著降低感染艾滋病毒的婴儿和儿童的发病率和死亡率。为了准确预测项目成本，分析师需要对儿童抗逆转录病毒药物(ARV)成本进行准确估计。然而，儿科抗逆转录病毒治疗的成本由于基于体重的剂量建议而变得复杂，这些建议随着儿童的成长而改变。我们开发了一种循序渐进的方法来估计0-13岁儿童的儿科ARV方案的成本。成本计算方法结合了基于体重的剂量建议，以提供整个儿童发育过程中估计的抗逆转录病毒剂量。然后，公布的单位药品成本被用来计算平均每月药品成本。我们将我们得出的每月ARV成本与公布的估计进行比较，以评估我们方法的准确性。考虑到三种可能的护理方案，提供了六种常用的一线儿科ARV方案的每月ARV费用估计。在我们的分析中得出的儿童费用相当于或略高于现有发表的ARV药物或方案估计值。这里描述的方法可用于准确估计儿科ARV方案的成本，以供成本效益分析人员预测HIV感染儿童的最佳护理方案，以及希望评估在有限预算环境下增加儿科ARV可获得性的项目管理员和预算分析师。
Pediatric antiretroviral therapy (ART) has been shown to substantially reduce morbidity and mortality in HIV-infected infants and children. To accurately project program costs, analysts need accurate estimations of antiretroviral drug (ARV) costs for children. However, the costing of pediatric antiretroviral therapy is complicated by weight-based dosing recommendations which change as children grow. We developed a step-by-step methodology for estimating the cost of pediatric ARV regimens for children ages 0–13 years old. The costing approach incorporates weight-based dosing recommendations to provide estimated ARV doses throughout childhood development. Published unit drug costs are then used to calculate average monthly drug costs. We compared our derived monthly ARV costs to published estimates to assess the accuracy of our methodology. The estimates of monthly ARV costs are provided for six commonly used first-line pediatric ARV regimens, considering three possible care scenarios. The costs derived in our analysis for children were fairly comparable to or slightly higher than available published ARV drug or regimen estimates. The methodology described here can be used to provide an accurate estimation of pediatric ARV regimen costs for cost-effectiveness analysts to project the optimum packages of care for HIV-infected children, as well as for program administrators and budget analysts who wish to assess the feasibility of increasing pediatric ART availability in constrained budget environments.
登录
查看更多内容
影响因子：
158.5
作者：
Palumbo, Paul;Lindsey, Jane C.;Violari, Avy
通讯作者：
Violari, Avy
一线治疗失败以及亚洲和南部非洲的一线小儿抗逆转录病毒通行与使用的一线治疗失败以及二线病毒的访问和审查。
影响因子：
6
作者：
TREAT Asia Pediatric HIV Observational Database (TApHOD);International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group
通讯作者：
International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group
影响因子：
3.8
作者：
Meyer-Rath, Gesine;Brennan, Alana;Rosen, Sydney
通讯作者：
Rosen, Sydney
影响因子：
1.2
作者：
Chokephaibulkit, Kulkanya;Cressey, Tim R.;Yogev, Ram
通讯作者：
Yogev, Ram
DOI：
10.1086/648079
发表时间：
2009-12-15
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Ciaranello AL;Chang Y;Margulis AV;Bernstein A;Bassett IV;Losina E;Walensky RP
通讯作者：
Walensky RP